## 1 Influenza A (H3) viral aerosol shedding in nasally inoculated and

### 2 naturally infected cases

- Jianyu Lai<sup>1\*</sup>, P. Jacob Bueno de Mesquita<sup>2</sup>, Filbert Hong<sup>1</sup>, Tianzhou Ma<sup>3</sup>, Benjamin J.
- 4 Cowling<sup>4</sup>, Donald K. Milton<sup> $1^*$ </sup>
- 5
- 6 1 Department of Global, Environmental, and Occupational Health, University of
- 7 Maryland School of Public Health, College Park, MD, USA
- 8 2 Department of Public Health, Roger Williams University, Bristol, RI, USA
- 9 3 Department of Epidemiology and Biostatistics, University of Maryland School of
- 10 Public Health, College Park, MD, USA
- 11 4 World Health Organization Collaborating Center for Infectious Disease
- 12 Epidemiology and Control, School of Public Health, The University of Hong Kong,
- 13 Hong Kong Special Administrative Region, China
- 14
- 15 \*Corresponding authors: Dr. Donald K. Milton, University of Maryland School of
- 16 Public Health, 4200 Valley Drive, College Park, MD 20742, USA email:
- 17 dmilton@umd.edu; Dr. Jianyu Lai, University of Maryland School of Public Health,
- 18 4200 Valley Drive, College Park, MD 20742, USA email: jlai12@umd.edu
- 19
- 20 Short title: Influenza A H3 viral aerosol shedding

It is made available under a CC-BY-NC 4.0 International license .

# 21 Abstract

22	Nasally inoculated influenza cases reported milder symptoms and shed lower viral
23	RNA load in exhaled breath aerosols (EBA) than people with classic influenza-like
24	illness including fever, in a previous study. Whether nasally inoculated influenza is
25	representative of mild natural influenza infection, the majority of natural infections, is
26	unknown. Here, we extend our previous analyses to include a broader range of
27	community-acquired influenza cases. Previously, we reported on two groups: (A)
28	volunteers intranasally inoculated with a dose of $5.5 \log_{10} TCID_{50}$ of influenza
29	A/Wisconsin/67/2005 (H3N2) and (B) cases with cough and sore throat plus fever or
30	a positive rapid antigen test recruited on a college campus in the same year (2013).
31	Here we added two additional groups from a later study: (C) cases from a 2017-2019
32	surveillance cohort of college dormitory residents and their contacts, and (D) cases
33	recruited from a university health center in 2019. All cases had an influenza A(H3)
34	infection. Using a Gesundheit-II sampler, we collected 30-minute EBA samples.
35	Community-acquired cases from the surveillance cohort (C) shed more EBA viral
36	RNA and were more symptomatic than the nasally inoculated cases (A) but shed less
37	viral RNA than the natural cases that were selected for symptoms (B) in 2013, but not
38	(D) recruited in 2019. Despite sharing a similar symptomatic profile with the 2013
39	selected natural cases (B), the 2019 community-acquired cases (D) recruited post-
40	infection showed a lower fine aerosol viral RNA load. Nasal inoculation of influenza
41	virus did not reproduce EBA viral RNA shedding or symptoms observed in mild
42	natural infection. Circulating strains of influenza A(H3) may differ, year-to-year in
43	the extent to which symptomatic cases shed virus into fine aerosols. New models,

It is made available under a CC-BY-NC 4.0 International license .

- 44 including possibly aerosol inoculation, are needed to study viral aerosol shedding
- 45 from the human respiratory tract.

It is made available under a CC-BY-NC 4.0 International license .

# 46 Author Summary

47	In this study, we compared influenza A (H3) viral aerosol shedding in the exhaled
48	breath of four different groups of influenza cases: (A) volunteers given the influenza
49	virus intranasally, naturally infected (B) college community members with classic
50	influenza-like illness including fever recruited in 2013, (C) dormitory residents
51	undergoing active surveillance, and (D) patients from a university health center
52	recruited in 2019. We found that mild symptomatic cases among healthy college
53	students (C) released more viral RNA in their exhaled breath than those nasally
54	inoculated with influenza virus (A). We also observed that more symptomatic and
55	medically attended cases from different flu seasons (B and D), although reporting
56	similar symptom severity, shed different levels of viral RNA in their exhaled breath.
57	Our findings indicate that influenza viral aerosol shedding varies from season to
58	season. Most volunteers nasally inoculated at a high virus dose did not shed
59	detectable viral RNA in their exhaled breath or show symptoms, suggesting that nasal
60	inoculation may not accurately mimic natural infection. Our results highlight the need
61	for improved models to study the spread of influenza virus in aerosol forms.

It is made available under a CC-BY-NC 4.0 International license .

# 62 Introduction

63	Seasonal influenza virus infections impose a tremendous health burden (1–4). In the
64	United States alone, Centers for Disease Control and Prevention estimated that
65	influenza-related deaths ranged from 12,000 to 52,000 per season from 2010 to 2020,
66	with between 140,000 and 710,000 hospitalizations per season (5). Among the
67	influenza strains, A(H3N2) viruses often result in more severe disease burdens in
68	terms of morbidity and mortality compared to other strains, such as A(H1N1) and B
69	viruses (2).
70	
71	Existing research demonstrates the major role of aerosol inhalation in influenza
72	transmission (6,7). One study estimated that approximately half of influenza
73	transmissions in households occur via inhalation of aerosols (6). Experimental
74	influenza cases infected via intranasal inoculation of viruses typically shed lower
75	levels of fine and coarse EBA than naturally-infected symptomatic influenza cases
76	(7,8), and experience milder symptoms compared to those infected naturally (8,9) or
77	via aerosol inoculation (10). Influenza A viral shedding quantity typically aligns with
78	the progression of clinical symptoms over the course of the disease (8,11). For
79	instance, the peaks of EBA viral shedding and symptom scores were observed on day
80	one post symptom onset for selected natural cases and on the third day post-
81	inoculation for experimental cases (8).
82	
83	Prior research comparing viral shedding between natural and intranasally inoculated
84	influenza cases has primarily focused on naturally infected cases presenting with

It is made available under a CC-BY-NC 4.0 International license .

85	acute respiratory illness, a fever or a positive rapid antigen test (8,9). This tendency to
86	recruit symptomatic cases from the population for aerosol shedding studies led to a
87	lack of data on those with mild or asymptomatic influenza viral infection.
88	Additionally, there has been limited comparative research on EBA viral shedding
89	trajectories for both natural cases unselected for symptoms and experimental nasal
90	inoculated cases. Despite observations that experimentally infected cases shed less
91	virus in EBA than naturally infected cases, there is a lack of overlap in symptom
92	severity between the two groups, with the experimentally infected cases mostly
93	presenting with mild illness or asymptomatically (8). The observed relationship
94	between symptom severity and exhaled breath viral shedding was potentially
95	confounded by the distinct populations under study, one being naturally infected and
96	the other infected via nasal inoculation.
97	

98 This study sought to address these limitations by broadening the scope of prior 99 analyses. We included unselected community-acquired influenza cases from a 100 surveillance cohort of college dormitory residents and their contacts. This group was 101 defined as "unselected" due to being enrolled and followed up for cold or flu-like 102 symptoms regularly, with validated incentives for consistent responses (12). We also 103 included cases recruited post infections from a university health center, who generally 104 presented with more symptoms. We compared these two groups with volunteers 105 intranasally inoculated with influenza A/Wisconsin/67/2005(H3N2) as well as 106 selected naturally infected influenza cases with cough and sore throat plus fever or a 107 positive rapid antigen test recruited in 2013 that were reported previously (8). Our

It is made available under a CC-BY-NC 4.0 International license .

- 108 aim was to examine the EBA viral shedding in an unselected sample of community-
- 109 acquired influenza cases and compare the EBA viral RNA loads and their trajectories
- 110 between nasally inoculated cases and different community-acquired influenza cases.
- 111

## 112 **Results**

## 113 *Characteristics of the study population*

- 114 This study included a total of 143 participants infected with influenza A(H3), with 36
- nasally inoculated with influenza A/Wisconsin/67/2005(H3N2) (Group A), 83
- selected symptomatic cases with fever or positive antigen test recruited in 2013
- 117 (Group B), 17 unselected cases recruited from the surveillance dorm resident cohort
- 118 (Group C), and 7 symptomatic cases recruited from a university health center (UHC)
- 119 in 2019 (Group D) (Figure 1). Group A had the most participants over 25 years of age
- 120 (mean age: 30.1 years), while the other three groups predominantly consisted of
- 121 younger adults, aged 18 to 25 years. A higher proportion of females was found in
- 122 Groups B (57%) and C (65%) compared to Groups A (31%) and D (29%) (Table 1
- 123 and Supplementary Table 1).
- 124

125	Table 1.	Characteristics	of the	study population
-----	----------	-----------------	--------	------------------

	A: Nasal	B:	C:	D:	All
	Inoculation	Symptoma	Surveillan	Symptomat	participa
	with	tic with	ce cohort	ic, seeking	nts
	influenza	T>37.8°C	with any	medical	
	A/Wisconsin	or positive	symptoms	care	
	/67/2005	antigen	and		
		test	positive		
			PCR		
Number of	36	83	17	7	143

83 (100)

0(0)

0(0)

0(0)

47 (57)

 $22.3 \pm 7.6$ 

2(2)

73 (88)

8 (10)

17 (20)

participants Influenza Season, N(%)

2012-2013

2016-2017 2017-2018

2018-2019

Female.

mean  $\pm$  SD

Age group, N(%)

<18

>25

With fever >

37.9°C,

18-25

N (%)

Age,

36 (100)

0(0)

0(0)

0(0)

11 (31)

 $30.1 \pm 7.2$ 

0(0)

11 (31)

25 (69)

1 (3)

It is made available under a	CC-BY-NC 4.0	International license

0(0)

3 (18)

4 (24)

10 (59)

11 (65)

 $19.3 \pm 0.9$ 

0 (0)

17 (100)

0(0)

2 (12)

0(0)

0(0)

0(0)

7 (100)

2 (29)

 $20 \pm 1.4$ 

0(0)

7 (100)

0(0)

1(14)

119 (83)

3 (2)

4 (3)

17 (12)

71 (50)

 $23.8 \pm$ 

7.8

2(1)

108 (76) 33 (23)

21 (15)

 $19 \pm 29$ 

(0-265)

 $37.2 \pm$ 

 $N(\%)^{a}$ Coughs per  $2\pm 6$  $27 \pm 33$  $13 \pm 18$  $15 \pm 21$ 30 min. (0-35)(0-265)(0-66)(0-60)mean± SD (range)<sup>b</sup>  $37.6\pm0.7$ Temperature  $36.6 \pm 0.6$  $37.3\pm0.6$  $37.3\pm0.8$  $(\mathbf{C})$ 

(C),					0.7
mean $\pm$ SD <sup>c</sup>					
Median	1	7	6	5	5
upper	(0 - 3)	(5 - 9)	(4 - 7)	(3.5 - 6.5)	(3 - 8)
respiratory					
symptoms					
$(IQR)^d$					
Median	0	3	3	2	2
lower	(0 - 0)	(2 - 4)	(2 - 3)	(2 - 4.5)	(1 - 4)
respiratory					
symptoms					
(IQR)					
Median	0	5	3	6	4
systemic	(0 - 1)	(4 - 7)	(1 - 6)	(4 - 7.5)	(1 - 6.5)
symptoms					
(IQR)					

126 a. Fever at the time of breath sample collection. Tympanic temperature was

measured for Group A and oral temperature was measured for Groups B, C, andD. One subject in Group C did not have body temperature measured.

b. Cough counts were missing for 4 observations in Group A, 3 observations in

130 Group B, and 3 observations in Group C.

It is made available under a CC-BY-NC 4.0 International license .

131 c. Temperature was missing for 1 observation in each of Groups A, B, and C.

132 d. Upper respiratory symptoms (range 0-15): runny nose, stuffy nose, sneezing, sore

- throat, and earache symptom scores; lower respiratory symptoms (range 0-6):
- shortness of breath and cough; systemic symptoms (range 0-9): malaise, headache,
- 135 and muscle/join ache.
- 136

137	As previously reported (8), Group A had very mild or non-existent symptoms. This
138	group had the lowest median score for all the three symptoms – upper respiratory
139	symptoms, lower respiratory symptoms, and systemic symptoms. They also had the
140	lowest incidence of febrile cases (3%) and a reduced frequency of coughs at the time
141	of sampling. Group C, the unselected community-acquired cases from the
142	surveillance cohort, demonstrated a medium level of symptom severity across the
143	groups. Specifically, we found a significant difference among the three community-
144	acquired infection groups in terms of their systemic symptoms and a borderline
145	significant difference for upper respiratory symptoms (Supplementary Table 1).
146	Group C had significantly lower upper respiratory and systematic symptom scores
147	than Group B. For Group B and D, the symptom distribution, as well as other
148	characteristics reported, did not demonstrate substantial differences (Table 1,
149	Supplementary Table 1, and Supplementary Figure 1).

150

## 151 *Positive detection rates and geometric means of EBA viral shedding*

152 Group A demonstrated a significantly lower rates of positive detection for both coarse

and fine EBA, in terms of the number of positive samples and positive cases, than

154 Group B and D. Group C had a slightly higher proportion of positive cases and

155 samples than Group A, although the differences were not significant.

It is made available under a CC-BY-NC 4.0 International license .

156

157 There was no significant difference between Groups B and D in the proportions of

158 positive cases and positive EBA samples. When comparing to Group C, we only

159 found significant difference in the rates of positive cases and samples for fine EBA

160 between Groups B and C (Table 2).

161

162	Table 2.	Viral	shedding	into	exhaled	breath	aerosols
-----	----------	-------	----------	------	---------	--------	----------

	A: Nasal Inoculation with influenza A/Wisconsin/67/2005		B: Symptomatic with T>37.8°C or positive antigen test		C: Surveillance cohort with any symptoms and positive PCR		D: Symptomatic, seeking medical care	
Year	2013		201	3	2017-2019		2019	
EBA	Coarse	Fine	Coarse	Fine	Coarse	Fine	Coarse	Fine
Cases	36	36	83	83	17	17	7	7
Samples	64	64	143	143	21	21	7	7
No. of positive cases (%)	6 (17)	11 (31)	43 (52)	71 (86)	5 (29)	8 (47)	4 (57)	6 (86)
No. of positive samples (%)	6 (9)	14 (22)	64 (45)	110 (77)	5 (24)	8 (38)	4 (57)	6 (86)

163

164 Figure 2 shows geometric mean viral RNA copy numbers measured in aerosols

165 collected per 30-mimute sampling period. In this analysis without controlling for

166 confounders, Group A had a significantly lower geometric mean viral RNA copy

167 numbers in both fine and coarse EBA, relative to the other three groups (Figure 2).

168 Group B presented a significantly higher geometric mean viral RNA copy numbers in

169 fine, but not in coarse EBA, compared to Group C and D. Both Group C and D

It is made available under a CC-BY-NC 4.0 International license .

170 displayed intermediate levels of fine EBA viral RNA load, although D had a higher

171 value than C.

172

### 173 Temporal Patterns of Symptoms and EBA Viral RNA Shedding

- 174 For Groups B, C, and D, symptom scores peaked on the first day following symptom
- 175 onset, with the exception of upper respiratory symptom scores in Group C, which

176 fluctuated post-onset. For Group A, all symptom scores reached their peak on the

177 third day post-inoculation. Based on the observed trajectories, we estimate an

- 178 incubation period of two days for Group A (Figure 3).
- 179

180 The trajectories of EBA viral RNA shedding mirrored those of the symptom scores,

181 with the exception of Group C. For this group, the EBA shedding trajectory followed

182 the symptom trajectory for the initial two days, but then increased on the third day

- 183 post-symptom onset (Figure 4).
- 184

#### 185 <u>Modeling Group Effects on EBA Viral RNA Shedding</u>

186 In models controlling for potential confounding variables and effect modifiers (age,

187 sex, and study days), Group A continued to present a significantly lower viral RNA

188 load in both aerosol fractions. The ratio of viral RNA shedding of Group A to that of

189 Group C was the lowest, with a value of  $3.3 \times 10^{-2}$  (95%CI:  $1.1 \times 10^{-3}$ , 0.99) for fine

aerosol and 9.5 x  $10^{-4}$  (95%CI: 4.4 x  $10^{-6}$ , 0.21) for coarse aerosol. Group B, on the

191 other hand, had a significantly higher viral RNA load in both aerosols compared to

It is made available under a CC-BY-NC 4.0 International license .

192	Group C, with the ratio as $2.2 \times 10^3$ (95% CI: $1.7 \times 10^2$ , $2.8 \times 10^4$ ) for fine and 88
193	$(95\%$ CI: 1.6, $4.8x10^3$ ) for coarse aerosols. There was no significant difference
194	between Group C and Group D in terms of viral RNA load in both EBA size fractions
195	(Figure 5 and Supplementary Table 2). Contrast analysis revealed that Group B had a
196	significantly higher viral load in fine aerosols than Group D, although no significant
197	difference was found for coarse aerosols (Supplementary Table 3).
198	
199	Regarding shedding trajectories over time, no significant difference was observed
200	between Group C and the rest of the groups concerning the dynamics of EBA viral
201	RNA shedding by study days (Supplementary Table 4).
202	

203 Discussion

204 This study provides a unique comparison of EBA viral shedding pattern among

205 influenza A/H3 infected individuals in distinct groups: nasally inoculated cases,

206 unselected community-acquired cases from a surveillance cohort, and selected natural

207 cases from different influenza seasons. We found previously that selected natural

208 cases shed higher viral load in EBAs and were more symptomatic than experimental

209 cases (8). This study further adds that unselected community-acquired cases,

210 representing a wider spectrum of symptom severity, shed more viral RNA in their

211 exhaled breath aerosols and were more symptomatic than the experimental, nasally

212 inoculated cases as well, but on average shed less viral RNA than the selected natural

213 cases that were more symptomatic and from different influenza season.

214

It is made available under a CC-BY-NC 4.0 International license .

215	Those inoculated nasally with a high dose of influenza virus A/Wisconsin/67/2005
216	strain had a high percentage of people who did not have detectable level of viral RNA
217	load in their exhaled breath aerosols or have any symptoms, despite shedding
218	substantial virus into nasopharyngeal swabs. This indicates that nasal inoculation with
219	this strain may not provide a robust model for understanding EBA viral shedding
220	patterns or the range of symptom severity typical in natural influenza virus infections.
221	Given the major role of aerosol inhalation in influenza transmission (6,7), inoculation
222	via aerosol inhalation might offer a more representative model for mimicking natural
223	influenza infections (13). Previous studies showed that inhalation of various strains of
224	influenza viruses led to fevers in human subjects, a response rarely seen with
225	intranasal instillation (14). Also, animal studies have demonstrated that aerosol
226	inhalation of recombinant influenza viruses results in a more efficient infection of the
227	lower respiratory tract and faster viral replication compared to intranasal inoculation
228	(15). This might explain the lower viral load found in the exhaled breath aerosols of
229	individuals inoculated intranasally, as opposed to those infected naturally.
230	
231	Of note, despite sharing a similar characteristic and symptomatic profile, the two
232	groups of medically attended cases from different years (Groups B and D) exhaled
233	statistically different fine aerosol viral RNA loads. The discrepancy in the
234	relationship between viral shedding and symptoms could be related to year-to-year
235	differences in circulating strains of influenza A(H3). The elevated viral load in fine
236	aerosols observed in participants from the 2012-2013 influenza season might, in part,
237	explain the heavier influenza burden during that season compared to the 2018-2019

It is made available under a CC-BY-NC 4.0 International license .

238	influenza season in the United States (5). This discovery underscores the importance
239	of monitoring influenza virus strains, even within the same influenza A(H3) subtype,
240	to better inform public health measures to mitigate the impact of future influenza
241	seasons and protect vulnerable populations more effectively.
242	
243	This study had several strengths. We did a unique comparison of EBA viral shedding
244	pattern among influenza A(H3) infected individuals from three sources, allowing us
245	to compare the viral shedding between experimental infections and the full range of
246	ambulatory community-acquired influenza virus infections. Including participants
247	from different years also allowed us to explore the difference between different
248	strains of influenza A(H3).
249	
250	Our research was subject to some limitations. Our study volunteers were all
251	ambulatory; hence the results of this study may not be generalizable to those who are
252	critically ill. We did not have culture results for all the EBA samples, hence we could
253	not directly compare infectious viral load, and potentially the risk of inhalation
254	transmission, among the groups. Despite this, previous work reported a correlation
255	between viral RNA and quantitative culture (7).
256	
257	This study reveals that the route of infection and strain difference could contribute to
258	the level of viral aerosol shedding in influenza virus infections. We highlight the need
259	for new models to study viral aerosol shedding from the human respiratory tract. In

260 particular, aerosol inoculation may represent a promising avenue for future research,

It is made available under a CC-BY-NC 4.0 International license .

- as this approach could better mimic natural infection process and offer insights into
- aerosol transmission dynamics. Overall, this study contributes to the broader
- understanding of viral shedding patterns in EBA and underscores the importance of
- 264 developing robust models to further our understanding of influenza transmission.
- 265

## 266 Materials and Methods

- 267 *Data sources and sample groups*
- 268 This study used data obtained from three studies. The first two of these studies -
- 269 Evaluating Modes of Influenza Transmission challenge study (EMIT-1 experimental
- study) (16), and an observational study of selected acute respiratory illness (ARI)
- 271 cases (EMIT-1 campus study) (7) have been previously reported (8). The third study
- followed uninfected volunteers over an academic year for their ARI occurrence,
- known as the Prometheus study (12).
- 274

#### 275 EMIT-1 experimental study

- 276 This study, initiated in 2013 to investigate questions related to influenza transmission
- 277 (16), involved volunteers divided into two groups: "Donors" and "Recipients". The
- 278 Donors were intranasally inoculated with a dose of 5.5 log<sub>10</sub>TCID<sub>50</sub> influenza
- A/Wisconsin/67/2005 and subsequently confirmed to have an influenza A infection
- 280 (H3N2). After inoculation, the Donors were paired with uninfected healthy Recipients
- in a common room to encourage interaction (16). For the purposes of this report, we
- exclusively included the Donors, representing experimental cases, and have
- 283 designated them as Group A.

It is made available under a CC-BY-NC 4.0 International license .

284

#### 285 EMIT-1 campus study

286	The EMIT-1 campus study was conducted at the University of Maryland, College
287	Park (UMD) (7,8). Volunteers presenting symptoms of acute respiratory infections
288	were recruited from December 2012 to March 2013. Those who eventually provided
289	breath samples were within 3 days of symptom onset, and had a positive QuickVue
290	Influenza A + B test (Quidel, San Diego, CA) or were still febrile with an oral
291	temperature of greater than 37.8 °C plus coughing or a sore throat (7,8). In the context
292	of our current study, we incorporated those with a positive nasopharyngeal swab for
293	influenza A/H3N2 as confirmed by reverse transcription polymerase chain reaction
294	(RT-PCR). This group, representing the severe spectrum of symptoms, was classified
295	as Group C.

296

#### 297 *Prometheus study*

298 The Prometheus study was also conducted at the UMD community (12). From 2017 299 to 2020, students and staff from UMD were actively recruited and monitored for the 300 occurrence of acute respiratory infections during each academic year. Volunteers 301 were instructed to report to the study team immediately upon developing cold or flu-302 like symptoms. The identified volunteers and their close contacts were then invited to 303 a research clinic to provide samples for further examination. For the 2018-2019 flu 304 season, additional volunteers were recruited from the university health center, 305 typically presenting with more severe symptoms than those recruited from the 306 surveillance cohort. For this study, we included individuals with confirmed influenza

It is made available under a CC-BY-NC 4.0 International license .

307	A via mid-turbinate or nasal and/or throat swabs, as identified by a TaqMan® Array
308	Card (Thermo Fisher, Waltham, MA, USA). Participants from the community,
309	generally presenting with very mild symptoms, were assigned to Group B1, while
310	those recruited from the university health center were classified as Group B2.
311	
312	Sample Collection
313	For all these studies, volunteers with confirmed viral infections were invited to
314	provide 30-minute EBA samples using a Gesundheit-II sampler (17). They were
315	allowed to breathe normally and cough spontaneously during the collection. After
316	collection, EBA samples were categorized by size into two fractions: fine aerosols
317	(diameter $\leq$ 5 µm) and coarse aerosols (>5 µm). Viral RNA was extracted from both
318	fine and coarse aerosol samples and quantified using real-time RT-PCR.
319	<u>Statistical analyses</u>
320	In our statistical analysis, we included only EBA samples on which day their nasal
321	and/or throat swabs were positive.
322	
323	Descriptive analysis was carried out for the four comparison groups (A, B1, B2, and
324	C). We compared the four groups and the three natural infection groups using
325	Kruskal-Wallis test for the continuous variables and Fisher's exact test for the
326	categorical variables. We also did pair-wise comparison among the three natural
327	infection groups, using T-test for the continuous variables and Fisher's exact test or
328	Chi-square test for the categorical variables.

It is made available under a CC-BY-NC 4.0 International license .

329

330	To visualize change over time, we plotted the EBA viral RNA loads as well as
331	symptom scores by study day for the four groups separately. The study day was
332	defined as days post symptom onset for Group B1, B2, and C and days post
333	inoculation for Group A, as most of the experimental cases were asymptomatic or not
334	sampled on the days after symptom onset. We then identified the incubation period $(I)$
335	for Group A by comparing the peak of symptom scores in Group A and the other
336	three groups.
337	
338	Linear mixed effect models with censored responses (R package 'lmec', version 1.0
339	(18)) were used to calculate the geometric means (GM) of the EBA viral RNA load
340	for the four comparison groups. These models accounted for the censored outcome
341	variable (i.e., viral RNA load below limit of detection) as well as nested random
342	effects of individuals and samples within the same individuals. We also used the lmec
343	model to estimate the group effect on EBA viral shedding (Model I) and the shedding
344	over time (Model II), controlling for potential confounders and effect modifiers. For
345	Model I, age, sex, and study day (defined as day post symptom onset for Group B1,
346	B2, and C, and day post inoculation minus $I$ for Group C) were included into the
347	models as potential confounders. Then the product terms of each of these three
348	variables and the group variable were included for further interaction assessment. The
349	best models were selected based on Akaike Information Criterion (AIC). For Model
350	II, we forced the interaction terms of group and study day into the model along with
351	age and sex, and then further selected the final model based on AIC.

It is made available under a CC-BY-NC 4.0 International license .

2	5	0
Э	J	L

- 353 We conducted all analyses in R version 4.2.3 (R Foundation for Statistical Computing,
- 354 Vienna, Austria) and RStudio.
- 355

#### 356 Acknowledgement

- 357 We thank all the members of the EMIT Consortium and Prometheus-UMD
- 358 investigators (Both complete lists of the members can be found in the Supporting
- 359 Materials).
- 360

## 361 Funding

- 362 Elements of this work were supported by Cooperative Agreement 1U01IP000497
- 363 from the US Centers for Disease Control and Prevention, by the Defense Advanced
- 364 Research Projects Agency (DARPA) BTO under the auspices of Col. Matthew
- 365 Hepburn through agreements N66001-17-2-4023 and N66001-18-2-4015, by the
- 366 Office of the Assistant Secretary for Preparedness and Response, Biomedical
- 367 Advanced Research and Development Authority, by the National Institute of Allergy
- 368 and Infectious Diseases Centers of Excellence for Influenza Research and
- 369 Surveillance (CEIRS) Contract Number HHSN272201400008C, and by gifts from
- 370 The Flu Lab and Balvi Filanthropic Fund. The findings and conclusions in this report
- are those of the authors and do not necessarily represent the official position or policy
- 372 of these funding agencies and no official endorsement should be inferred.
- 373

It is made available under a CC-BY-NC 4.0 International license .

#### 374 **Declaration of interests**

- 375 B.J.C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna,
- 376 Novavax, Pfizer, Roche, and Sanofi Pasteur. D.K.M. consults for A.I.R LLC and
- 377 holds stock options for Lumen Bioscience, Inc. The authors declare no other
- 378 competing interests.

#### 379 **References**

- 380 1. Centers for Disease Control and Prevention (CDC). Estimates of deaths
- associated with seasonal influenza --- United States, 1976-2007. MMWR Morb
- 382 Mortal Wkly Rep. 2010 Aug 27;59(33):1057–62.
- 2. Chowell G, Miller MA, Viboud C. Seasonal influenza in the United States,
- France, and Australia: transmission and prospects for control. Epidemiology &
  Infection. 2008 Jun;136(6):852–64.
- 386 3. Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA, et al.
- 387 Annual estimates of the burden of seasonal influenza in the United States: A tool
- 388 for strengthening influenza surveillance and preparedness. Influenza Other Respir
- 389 Viruses. 2018 Jan;12(1):132–7.
- 390 4. Taniguchi K, Ikeda S, Hagiwara Y, Tsuzuki D, Klai M, Sakai Y, et al.
- 391 Epidemiology and burden of illness of seasonal influenza among the elderly in
- 392 Japan: A systematic literature review and vaccine effectiveness meta-analysis.
- 393 Influenza and Other Respiratory Viruses. 2021;15(2):293–314.

It is made available under a CC-BY-NC 4.0 International license .

394	5.	Centers for Disease Control and Prevention. Centers for Disease Control and
395		Prevention. 2021 [cited 2021 Dec 24]. Burden of Influenza. Available from:
396		https://www.cdc.gov/flu/about/burden/index.html
397	6.	Cowling BJ, Ip DKM, Fang VJ, Suntarattiwong P, Olsen SJ, Levy J, et al.
398		Aerosol transmission is an important mode of influenza A virus spread. Nat
399		Commun. 2013;4(1):1935.
400	7.	Yan J, Grantham M, Pantelic J, Bueno de Mesquita PJ, Albert B, Liu F, et al.
401		Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a
402		college community. Proc Natl Acad Sci USA. 2018 Jan 30;115(5):1081-6.
403	8.	Bueno de Mesquita PJ, Nguyen-Van-Tam J, Killingley B, Enstone J, Lambkin-
404		Williams R, Gilbert AS, et al. Influenza A (H3) illness and viral aerosol shedding
405		from symptomatic naturally infected and experimentally infected cases. Influenza
406		Other Respir Viruses. 2021 Jan;15(1):154–63.
407	9.	Little JW, Douglas RG, Hall WJ, Roth FK. Attenuated influenza produced by
408		experimental intranasal inoculation. J Med Virol. 1979;3(3):177-88.
409	10.	Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from
410		aerosol inhalation. Proc Soc Exp Biol Med. 1966 Jul;122(3):800-4.
411	11.	Ip DKM, Lau LLH, Chan KH, Fang VJ, Leung GM, Peiris MJS, et al. The
412		Dynamic Relationship Between Clinical Symptomatology and Viral Shedding in
413		Naturally Acquired Seasonal and Pandemic Influenza Virus Infections. Clin
414		Infect Dis. 2016 Feb 15;62(4):431–7.

It is made available under a	CC-BY-NC 4.0	International	license
------------------------------	--------------	---------------	---------

- 415 12. Adenaiye O, Bueno de Mesquita PJ, Wu Q, Hong F, Lai J, Chen S, et al. The
- 416 effect of COVID-19 stay-at-home order and campus closure on the prevalence of
- 417 acute respiratory infection symptoms in college campus cohorts. Influenza Other
- 418 Respir Viruses. 2021 May;15(3):331–5.
- 419 13. Belser JA, Gustin KM, Katz JM, Maines TR, Tumpey TM. Comparison of
- 420 traditional intranasal and aerosol inhalation inoculation of mice with influenza A
- 421 viruses. Virology. 2015 Jul;481:107–12.
- 422 14. Henle W, Henle G, Stokes J, Maris EP. Experimental Exposure of Human
- 423 Subjects to Viruses of Influenza. J Immunol. 1946;52(2):145–65.
- 424 15. Zhang Y, Guo Z, Wang Z, Fu Y, Zhao Z, Liu L, et al. Comparison of traditional
- 425 intranasal and aerosol inhalation inoculation of guinea pigs with visualizing

426 influenza virus. Journal of Aerosol Science. 2017 Aug 1;110:43–52.

- 427 16. Jonathan S. Nguyen-Van-Tam, Ben Killingley, Joanne E. Enstone, Michael
- 428 Hewitt, Jovan Pantelic, Michael L. Grantham, et al. Minimal transmission in an
- 429 influenza A (H3N2) human challenge-transmission model within a controlled

430 exposure environment. PLOS Pathogens. 2020 Jul 13;16(7).

- 431 17. McDevitt JJ, Koutrakis P, Ferguson ST, Wolfson JM, Fabian MP, Martins M, et
- 432 al. Development and Performance Evaluation of an Exhaled-Breath Bioaerosol
- 433 Collector for Influenza Virus. Aerosol Sci Technol. 2013 Jan 1;47(4):444–51.

It is made available under a CC-BY-NC 4.0 International license .

- 434 18. Liu FV and L. Imec: Linear Mixed-Effects Models with Censored Responses
- 435 [Internet]. 2012 [cited 2022 Apr 30]. Available from: https://CRAN.R-
- 436 project.org/package=lmec

It is made available under a CC-BY-NC 4.0 International license .

#### 438 **Figures**



It is made available under a CC-BY-NC 4.0 International license .

442



443

444 Figure 2. Geometric means of EBA viral shedding for the four groups

445 GM, geometric means; GSD, geometric standard deviation. Group A: Nasal

446 Inoculation with influenza A/Wisconsin/67/2005; Group B: Symptomatic with

447 T>37.8°C or positive antigen test; Group C: Surveillance cohort with any symptoms

448 and positive PCR; Group D: Symptomatic, seeking medical care. The GM and GSD

449 were computed for all the samples using linear mixed-effects models for censored

450 responses (R Project package "lmec"). These models accounted for the censored

451 outcome variable as well as nested random effects of individuals and samples within

the same individuals.

It is made available under a CC-BY-NC 4.0 International license .

453



456 Group A: Nasal Inoculation with influenza A/Wisconsin/67/2005; Group B:

457 Symptomatic with T>37.8°C or positive antigen test; Group C: Surveillance cohort

458 with any symptoms and positive PCR; Group D: Symptomatic, seeking medical care.

- 459 Study day was defined as day post symptom onset for Group B, C, and D, and day
- 460 post inoculation for Group A.
- 461

It is made available under a CC-BY-NC 4.0 International license .

462



465 Group A: Nasal Inoculation with influenza A/Wisconsin/67/2005; Group B:

466 Symptomatic with T>37.8°C or positive antigen test; Group C: Surveillance cohort

467 with any symptoms and positive PCR; Group D: Symptomatic, seeking medical care.

468 Study day was defined as day post symptom onset for Group B, C, and D, and day

- 469 post inoculation for Group A.
- 470
- 471

It is made available under a CC-BY-NC 4.0 International license .

472



Figure 5. The ratio of viral shedding in EBA of selected and inoculated cases to
shedding by unselected cases (Group B1), controlling for age, sex, and study
days

477 Group A: Nasal Inoculation with influenza A/Wisconsin/67/2005; Group B:

478 Symptomatic with T>37.8°C or positive antigen test; Group C: Surveillance cohort
479 with any symptoms and positive PCR; Group D: Symptomatic, seeking medical care.

480 We included only those samples whose study day was not missing (three C and one D

481 cases were excluded due to not having symptom onset date on file or having no

- 482 symptoms over the course of the follow-up period). We used linear mixed-effects
- 483 models for censored responses (R Project package "lmec") to estimate the ratio of
- 484 viral shedding in EBA of Group A/B/D to Group C. These models accounted for the
- 485 censored outcome variable as well as nested random effects of individuals and

It is made available under a CC-BY-NC 4.0 International license .

- 486 samples within the same individuals. The best models were selected based on Akaike
- 487 Information Criterion (AIC).

It is made available under a CC-BY-NC 4.0 International license .

## 489 Supplementary materials

#### 490 EMIT Consortium Team Members

- 491 EMIT team members were: Walt Adamson, Blanca Beato-Arribas, Werner Bischoff,
- 492 William Booth, Simon Cauchemez, Sheryl Ehrman, Joanne Enstone, Neil Ferguson,
- 493 John Forni, Anthony Gilbert, Michael Grantham, Lisa Grohskopf, Andrew Hayward,
- 494 Michael Hewitt, Ashley Kang, Ben Killingley, Robert Lambkin-Williams, Alex
- 495 Mann, Donald Milton, Jonathan Nguyen-Van-Tam, Catherine Noakes, John Oxford,
- 496 Massimo Palmarini, Jovan Pantelic, and Jennifer Wang. The Scientific Advisory
- 497 Board members were: Allan Bennett, Ben Cowling, Arnold Monto, and Raymond
- 498 Tellier.
- 499
- 500
- 501

It is made available under a CC-BY-NC 4.0 International license .

## 502 **Prometheus-UMD investigators:**

- 503 Addo, Kofi
- 504 Adenaiye, Oluwasanmi Oladapo
- 505 Agrawala, Agrawala
- 506 Aiello, Allison
- 507 Albert, Barbara
- 508 Arria, Amelia
- 509 Bueno de Mesquita, P. Jacob
- 510 Cai, Mara
- 511 Chen, Shuo
- 512 Chen, Wilbur
- 513 Corrada Bravo, Hector
- 514 Elworth, Leo
- 515 Felgner, Philip
- 516 Frieman, Matthew
- 517 German, Jennifer
- 518 Heidarinejad, Mohammad
- 519 Hong, Filbert
- 520 Jiang, Chengsheng
- 521 Khan, Saahir
- 522 Lai, Jianyu
- 523 Liu, Hongjie
- 524 Ma, Tianzhou

It is made available under a CC-BY-NC 4.0 International license .

- 525 Maljkovic Berry, Irina
- 526 Martinello, Richard
- 527 Mattise, Nick
- 528 Memon, Atif
- 529 Milton, Donald
- 530 Mongodin, Emmanuel
- 531 Nasko, Dan
- 532 Pop, Mihai
- 533 Porter, Adam
- 534 Romo, Sebastian
- 535 Srebric, Jelena
- 536 Tai, Sheldon
- 537 Treangen, Todd
- 538 Wajid, Faizan
- 539 Washington-Lewis, Rhonda
- 540 Wu, Qiong
- 541 Xing, Yishi
- 542 Youssefi, Somayeh
- 543 Zhu, Shengwei

It is made available under a CC-BY-NC 4.0 International license .

# 544 Supplementary Tables

# 545 Supplementary Table 1. Group comparisons for the Characteristics of the study

## 546 population

	4-group	3-group			
	comparison <sup>a</sup>	comparison	C vs. D <sup>b</sup> ,	B vs. C,	B vs. D,
	(A, B, C, D),	(B, C, D),	р	р	р
	р	р			
Flu season	<0.001	<0.001	0.222	<0.001	< 0.001
Female	0.02	0.293	0.182	0.73	0.239
Age	<0.001	0.008	0.159	< 0.001	0.433
Age group	<0.001	0.695	1	0.549	1
With fever >	0.056	0.896	1	0.73	1
37.9°C					
Coughs per 30	<0.001	0.042	0.826	0.08	0.338
min					
Temperature	< 0.001	0.14	0.32	0.711	0.256
(C)					
Upper					
respiratory	<0.001	0.061	0.87	0.028	0.139
symptoms					
Lower					
respiratory	<0.001	0.403	0.498	0.146	0.939
symptoms					

It is made available under a CC-BY-NC 4.0 International license .

Systemic					
avmntoma	< 0.001	0.004	0.08	< 0.001	0.957
symptoms					

a. Four-group and three-group comparison: Kruskal-Wallis test for the continuous

548 variables and Fisher's exact test for the categorical variables

b. Two-group comparison: T-test for the continuous variables and Fisher's exact test

550 or Chi-square test for the categorical variables.

It is made available under a CC-BY-NC 4.0 International license .

#### 551 Supplementary Table 2. The effect of group (ref = Group C) on EBA viral RNA

## 552 shedding<sup>a,b</sup>.

Variables		Fine EBA	Coarse EBA	
	А	0.033 (0.0011, 0.99)	0.00095 (4.4e-06, 0.21)	
Group <sup>b</sup> (Ref=C)	В	2200 (170, 28000)	88 (1.6, 4800)	
	D	2.8 (0.048, 160)	3.9 (0.0072, 2100)	
Study Day <sup>c</sup>		0.27 (0.14, 0.52)	0.19 (0.079, 0.46)	
(DPS/DPI-2)				
Age		Age 1.1 (0.95, 1.2)		
Sex		8.2 (1.8, 36)	6.4 (0.65, 62)	

553 a. Group A: Nasal Inoculation with influenza A/Wisconsin/67/2005; Group B: 554 Symptomatic with T>37.8°C or positive antigen test; Group C: Surveillance cohort 555 with any symptoms and positive PCR; Group D: Symptomatic, seeking medical care. 556 b. We used linear mixed-effects models for censored responses (R Project package 557 "lmec") to estimate the ratio of viral shedding in EBA of Group A/B/D to Group C. 558 These models accounted for the censored outcome variable as well as nested random 559 effects of individuals and samples within the same individuals. The best models were 560 selected based on Akaike Information Criterion (AIC).

c. Study Day was defined as day post symptom onset for Group B, C, and D, and day
post inoculation minus two days for Group A. We included only those samples whose
study day was not missing (three C and one D cases were excluded due to not having
symptom onset date on file or having no symptoms over the course of the follow-up
period).

It is made available under a CC-BY-NC 4.0 International license .

It is made available under a CC-BY-NC 4.0 International license .

567

## 568 Supplementary Table 3. Contrast analysis on the relative effect of selected and

## 569 **inoculated cases**<sup>a</sup>

	Fine EBA			Coarse EBA		
	Contrast	Standard	p-value	Contrast	Standard	p-value
	coefficient	error		coefficient	error	
Group A vs. Group B	-11	1.2	<0.001	-11	1.9	4.3 x 10 <sup>-9</sup>
Group A vs. Group D	-4.4	2	0.025	-8.3	3.1	0.007
Group D vs. Group B	-6.7	1.7	0.00012	-3.1	2.7	0.24

a. Group A: Nasal Inoculation with influenza A/Wisconsin/67/2005; Group B:

571 Symptomatic with T>37.8°C or positive antigen test; Group D: Symptomatic, seeking 572 medical care.

It is made available under a CC-BY-NC 4.0 International license .

## 574 Supplementary Table 4. The effect of group (ref = Group C) on EBA viral RNA

## 575 shedding over study day<sup>a,b,c</sup>

Variables		Fine EBA	Coarse EBA
Group	A	0.0052 (1.7e-05, 1.6)	3.7 (4.6e-05, 310000)
(Ref=C)	В	1200 (4.9, 280000)	720000 (13, 4e+10)
	D	0.25 (4.5e-06, 14000)	11000 (0.00017, 6.5e+11)
Study Day (DPS/DPI- 2)		0.13 (0.0098, 1.8)	10 (0.11, 910)
Age		1.1 (0.95, 1.2)	1.1 (0.96, 1.3)
Sex		8.5 (1.9, 38)	4.7 (0.49, 45)
Group A x Study Day		10 (0.51, 210)	0.019 (0.00011, 3.4)
Group B x Study Day		1.5 (0.096, 22)	0.012 (0.00012, 1.2)
Group D x Study Day		4.7 (0.0035, 6300)	0.027 (3.7e-07, 1900)

### a. Group A: Nasal Inoculation with influenza A/Wisconsin/67/2005; Group B:

577 Symptomatic with T>37.8°C or positive antigen test; Group C: Surveillance cohort 578 with any symptoms and positive PCR; Group D: Symptomatic, seeking medical care. 579 b. We used linear mixed-effects models for censored responses (R Project package 580 "Imec") to model the effect of groups on viral shedding over time. These models 581 accounted for the censored outcome variable as well as nested random effects of 582 individuals and samples within the same individuals. The best models were selected 583 based on Akaike Information Criterion (AIC). None of the interaction terms 584 demonstrated a significant effect.

It is made available under a CC-BY-NC 4.0 International license .

- 585 c. Study Day was defined as day post symptom onset for Group B, C, and D, and day
- 586 post inoculation minus two days for Group A. We included only those samples whose
- 587 study day was not missing (three C and one D cases were excluded due to not having
- 588 symptom onset date on file or having no symptoms over the course of the follow-up
- 589 period).
- 590
- 591

It is made available under a CC-BY-NC 4.0 International license .

## 592 Supplementary Figure



593

## 594 Supplementary Figure 1. Mean symptom scores, body temperatures, and cough

## 595 counts across groups.

596 Group A: Nasal Inoculation with influenza A/Wisconsin/67/2005; Group B:

597 Symptomatic with T>37.8°C or positive antigen test; Group C: Surveillance cohort

598 with any symptoms and positive PCR; Group D: Symptomatic, seeking medical care.

599